2008
Prognostic Implications of Left Ventricular Mass and Geometry Following Myocardial Infarction The VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study
Verma A, Meris A, Skali H, Ghali JK, Arnold JM, Bourgoun M, Velazquez EJ, McMurray JJ, Kober L, Pfeffer MA, Califf RM, Solomon SD. Prognostic Implications of Left Ventricular Mass and Geometry Following Myocardial Infarction The VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study. JACC Cardiovascular Imaging 2008, 1: 582-591. PMID: 19356485, DOI: 10.1016/j.jcmg.2008.05.012.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiotensin II Type 1 Receptor BlockersCardiovascular DiseasesEuropeFemaleHeart VentriclesHumansHypertrophy, Left VentricularKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionPredictive Value of TestsProportional Hazards ModelsRecurrenceRisk AssessmentRisk FactorsTetrazolesTime FactorsTreatment OutcomeUltrasonographyUnited StatesValineValsartanVentricular RemodelingConceptsLeft ventricular mass indexRelative wall thicknessHigh-risk myocardial infarctionAdverse cardiovascular eventsLeft ventricular massMyocardial infarctionLV geometryCardiovascular eventsConcentric remodelingEchocardiographic studyLV hypertrophyConcentric hypertrophyEccentric hypertrophyPrognostic implicationsVentricular massBaseline left ventricular mass indexMean left ventricular mass indexBaseline left ventricular massHigher relative wall thicknessBaseline LV massNonfatal cardiovascular outcomesAbnormal LV geometryComposite end pointVentricular mass indexConcentric LV hypertrophy
2004
Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction
Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA. Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction. New England Journal Of Medicine 2004, 351: 1285-1295. PMID: 15385655, DOI: 10.1056/nejmoa041365.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsCaptoprilCardiovascular DiseasesChronic DiseaseCreatinineDouble-Blind MethodDrug Therapy, CombinationFemaleGlomerular Filtration RateHumansKidney DiseasesMaleMiddle AgedMyocardial InfarctionProportional Hazards ModelsRisk FactorsSurvival RateTetrazolesValineValsartanConceptsGlomerular filtration rateAcute myocardial infarctionMyocardial infarctionCardiovascular outcomesHeart failureRisk factorsAcute Myocardial Infarction trialFour-component ModificationNonfatal cardiovascular outcomesMyocardial Infarction trialUse of aspirinComposite cardiovascular eventsComposite end pointRenal Disease equationCongestive heart failureMild renal diseaseRisk of deathCoronary revascularization proceduresMajor risk factorSerum creatinine measurementsBody surface areaCardiovascular causesKillip classRenal eventsCardiovascular complications